

EXAMINER

Dr. Shamsheen

DATE CONSIDERED

12/2/16

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P20670	Serial No. 09/763,617
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant K. WANNER et al.	
		Filing Date September 3, 1999	Group 1626

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- 1 PAVIA, Michael R., et al.: Structure-Activity Studies on Benzhydrol-Containing Nipecotic Acid and Guvacine Derivatives as Potent, Orally-Active Inhibitors of GABA Uptake. In: J. Med. Chem. 1992, 35, pp 4238-4248;
 - 2 ANDERSEN, Knud Erik, et al.: The Synthesis of Novel GABA Uptake Inhibitors. 1. Elucidation of the Structure-Activity Studies Leading to Choice of (R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinocarboxylic Acid (Tiagabine) as an Anticonvulsant Drug Candidate. In: J. Med. Chem. 1993 pp. 1716-1725.
 - 3 Suzak, Peter D.: Lipophilic GABA uptake inhibitors: Biochemistry, pharmacology and therapeutic potential. In: Drugs of the Future 1993, 18(12), pp. 1129-1136;
 - 4 Murali Dhar, T.G., et al: Design, Synthesis and Evaluation of Substituted Triarylnipecotic Acid Derivatives as GABA Uptake Inhibitors: Identification of a Ligand with Moderate Affinity and Selectivity for the Cloned Human GABA Transporter GAT-3. In: J. Med. Chem. 1994, 37, pp. 2334-2342.
 - 5 Thomsen, C., et al.: 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. In: British Journal of Pharmacology (1997) 120, 983-985.

EXAMINER

Mr. Rameem

DATE CONSIDERED

123101

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.